uniQure (QURE) Competitors $16.49 -0.45 (-2.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$16.85 +0.36 (+2.18%) As of 09/12/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. MIRM, MLTX, MTSR, PTGX, AAPG, LNTH, AKRO, APLS, ZLAB, and CRNXShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Akero Therapeutics (AKRO), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Ascentage Pharma Group International Lantheus Akero Therapeutics Apellis Pharmaceuticals Zai Lab Crinetics Pharmaceuticals uniQure (NASDAQ:QURE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Do analysts rate QURE or MIRM? uniQure currently has a consensus price target of $37.45, indicating a potential upside of 127.13%. Mirum Pharmaceuticals has a consensus price target of $74.44, indicating a potential upside of 0.18%. Given uniQure's higher possible upside, equities research analysts plainly believe uniQure is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is QURE or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to uniQure's net margin of -1,387.98%. Mirum Pharmaceuticals' return on equity of -24.76% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,387.98% -1,010.74% -33.27% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Does the media refer more to QURE or MIRM? In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than uniQure. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 4 mentions for uniQure. Mirum Pharmaceuticals' average media sentiment score of 0.52 beat uniQure's score of 0.48 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in QURE or MIRM? 78.8% of uniQure shares are held by institutional investors. 4.8% of uniQure shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, QURE or MIRM? Mirum Pharmaceuticals has higher revenue and earnings than uniQure. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M33.36-$239.56M-$3.92-4.21Mirum Pharmaceuticals$336.89M11.08-$87.94M-$1.21-61.41 Which has more risk & volatility, QURE or MIRM? uniQure has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. SummaryMirum Pharmaceuticals beats uniQure on 12 of the 17 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$904.48M$3.16B$5.79B$10.19BDividend YieldN/A2.33%5.73%4.60%P/E Ratio-4.217.6256.5722.28Price / Sales33.36416.49529.93120.07Price / CashN/A44.4425.8129.91Price / Book-117.799.6112.166.25Net Income-$239.56M-$53.29M$3.29B$270.76M7 Day Performance-8.13%0.13%0.74%3.87%1 Month Performance4.50%5.55%5.00%5.49%1 Year Performance191.34%10.44%62.55%25.86% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure3.2062 of 5 stars$16.49-2.7%$37.45+127.1%+191.3%$904.48M$27.12M-4.21500MIRMMirum Pharmaceuticals3.1209 of 5 stars$76.06+2.5%$74.13-2.5%+80.7%$3.82B$336.89M-62.86140News CoveragePositive NewsAnalyst ForecastInsider TradeMLTXMoonLake Immunotherapeutics2.5003 of 5 stars$59.44-0.5%$74.43+25.2%+2.9%$3.82BN/A-21.382News CoverageHigh Trading VolumeMTSRMetseraN/A$35.87-1.2%$59.00+64.5%N/A$3.77BN/A0.0081Trending NewsAnalyst ForecastAnalyst RevisionPTGXProtagonist Therapeutics2.318 of 5 stars$60.53+1.6%$67.20+11.0%+25.2%$3.77B$434.43M86.47120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$40.50+5.0%N/AN/A$3.76B$134.35M0.00600Positive NewsLNTHLantheus4.5444 of 5 stars$54.75+1.7%$91.60+67.3%-49.8%$3.72B$1.53B14.56700Trending NewsShort Interest ↓AKROAkero Therapeutics3.8958 of 5 stars$44.72+1.6%$81.14+81.4%+59.0%$3.58BN/A-22.3630Analyst DowngradeInsider TradeAPLSApellis Pharmaceuticals4.2921 of 5 stars$28.13-1.8%$34.12+21.3%-33.9%$3.55B$781.37M-15.46770News CoveragePositive NewsZLABZai Lab3.0908 of 5 stars$30.76+2.5%$56.35+83.2%+59.9%$3.44B$398.99M-15.081,869News CoverageInsider TradeGap UpCRNXCrinetics Pharmaceuticals3.6669 of 5 stars$35.61+4.0%$68.86+93.4%-36.8%$3.35B$1.04M-8.66210Positive News Related Companies and Tools Related Companies MIRM Alternatives MLTX Alternatives MTSR Alternatives PTGX Alternatives AAPG Alternatives LNTH Alternatives AKRO Alternatives APLS Alternatives ZLAB Alternatives CRNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
